ROYALTY PHARMA PLC- CL A
RPRXNASDAQ🏆 #340 by market capEarnings Nov 4US Equity
$64.81▼ $0.48 (−0.74%)
Market closed · at closeTrack RPRX
Get earnings, price moves & breaking news on Telegram
24h▼ 0.7%
7d▲ 1.7%
14d▲ 8.7%
30d▲ 11.3%
ytd▲ 67.7%
1y▲ 76.7%
🏦Market Cap
$37.26B
Mid Cap
📈Revenue Growth (YoY)
10.0%
Healthy
📊Gross Margin
—
💵FCF Margin
33.0%
Strong
⚖️P/S Ratio
14.7x
Expensive
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $63.51 – $65.33
- 52-Week Range
- $35.92 – $65.51
- Volume (shares)
- 155,573
- Avg Volume (shares)
- —
- Shares Outstanding
- 575.0M
- Next Earnings
- 2026-11-04
Fundamentals Snapshot
- Annual Revenue
- $2.38B
- Last Q Revenue
- $674M
- P/E Ratio
- 45.8
- P/S Ratio
- 14.7x
- EPS (TTM)
- $1.46
- Dividend Yield
- 1.07%
- Dilution (1yr)
- −5.0%
ROYALTY PHARMA PLC- CL A
RPRXFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$2.4B▲ +5.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$1.6B▲ +20.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$2.5B▼ −10.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
559.6M▼ −5.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$8.3B▼ −$1.6B YoY
StockOtter · stockotter.spaceAbout ROYALTY PHARMA PLC- CL A
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.
Latest News & Updates
News unavailable.